Emma Hall, PhD, on Bladder Cancer: Results From the BC2001 Trial
2017 Genitourinary Cancers SymposiumEmma Hall, PhD, of the Institute of Cancer Research, London, discusses long-term outcomes with chemoradiotherapy vs radiotherapy alone, and standard vs reduced high-dose volume radiotherapy in muscle-invasive bladder cancer. (Abstract 280)
Related Videos
Guru Sonpavde, MD, on Prostate Cancer: Targeting DNA Alterations
Guru Sonpavde, MD, of the UAB Comprehensive Cancer Center, discusses his study on circulating tumor DNA alterations in metastatic castration-resistant prostate cancer and the therapeu...
Sumanta K. Pal, MD, on RCC and Tumor Profiling
Sumanta K. Pal, MD, of the City of Hope, discusses the evolution of circulating tumor DNA profile from first-line to second-line therapy in metastatic renal cell carcinoma. (Abstract ...
Toni K. Choueiri, MD, on Papillary RCC: Phase II Trial Results
Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, discusses a single-arm biomarker-based study of savolitinib in patients with advanced papillary renal cell cancer. (Abstract...
Roland Seiler, MD, on Bladder Cancer: Subtypes and Treatment Response (German Language Version)
Roland Seiler, MD, of the University of British Columbia, discusses in German a way to identify molecular subtypes of muscle-invasive bladder cancer, the varying responses to cisplati...
Karim Chamie, MD, on Bladder Cancer: Optimizing Surgical and Medical Therapies
Karim Chamie, MD, of the University of California, Los Angeles, discusses induction and maintenance BCG therapy in non–muscle-invasive bladder cancer.
